Welcome to our dedicated page for Alpha Tau Medical Ltd. Ordinary Shares news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical Ltd. Ordinary Shares stock.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is at the forefront of oncology therapeutics, specializing in the research, development, and potential commercialization of the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. Founded in 2016, this Israeli medical device company focuses on the innovative use of alpha radiation to treat solid tumors. The Alpha DaRT technology, initially developed at Tel Aviv University, has shown promising results in preclinical and early clinical trials for various types of cancer.
Core Business and Technology: The Alpha DaRT technology uses alpha-emitting radium-224 atoms to target and destroy cancer cells while sparing surrounding healthy tissue. This method involves inserting radioactive seeds into the tumor, which release short-lived alpha particles. These particles have high biological effectiveness and a short range, making them ideal for localized treatment of solid tumors.
The company's current clinical trials are focused on multiple cancer types, including pancreatic, liver, and recurrent cutaneous squamous cell carcinoma. These trials are being conducted in various locations, including the European Union and North America. Notably, Alpha Tau is advancing its pivotal U.S. multi-center trial, ReSTART, which aims to treat recurrent cutaneous squamous cell carcinoma, and is expected to produce significant data by 2024.
Recent Achievements: Alpha Tau has made substantial progress recently. In October 2023, the company announced a long-term lease agreement for a new manufacturing site in Hudson, New Hampshire, which will significantly boost its production capabilities. Additionally, the company reported promising interim results from its pancreatic cancer trial and treated its first patient with liver metastases in a feasibility and safety study in Montreal, Canada.
Financial Condition: As of September 30, 2023, the company reported cash, restricted cash, and deposits totaling $90.1 million, ensuring sufficient funds to support operations for at least two years. For the nine months ended September 30, 2023, R&D expenses were $18.9 million, reflecting increased investments in employee compensation, clinical trials, and pre-clinical studies.
Partnerships and Collaborations: Alpha Tau is also exploring strategic partnerships to expand its clinical and commercial footprint. Discussions with major biopharmaceutical companies are underway, particularly for the Japanese market, where the company has completed a successful clinical trial for head and neck cancers.
Forward-Looking Statements: The company remains committed to advancing its clinical programs and expanding its manufacturing capabilities. With a strong financial position and a pipeline of promising clinical trials, Alpha Tau is well-positioned to make significant strides in the fight against cancer.
For more information, visit Alpha Tau Medical Ltd.
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- First patient treated for liver metastases from colorectal cancer in May
- Publication in Cancers journal showing nearly 100% overall response rate in treated lesions
- Cash balance of $74.1 million, providing at least two years of runway
- ReSTART U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma progressing
- Ongoing internal organ trials generating strong clinician interest
- New manufacturing plant in Hudson, NH approved and under renovation
Financial results for H1 2024 show R&D expenses of $13.3 million, marketing expenses of $1.1 million, and G&A expenses of $3.0 million. Net loss was $15.4 million ($0.22 per share), compared to $16.9 million ($0.24 per share) in H1 2023.
Alpha Tau announced the publication of long-term safety and efficacy data for its Alpha DaRT™ cancer therapy in the journal Cancers. The pooled analysis included 81 patients with hard-to-treat skin, head and neck, and oral cavity cancers from four international clinical trials. The results demonstrated an overall response rate of 99%, with a complete response rate of 89% and a 10% partial response rate. No moderate or severe long-term toxicities were observed, and the two-year local recurrence-free survival was estimated at 77%. Follow-up spanned up to 51 months, with a median of 14 months. The study suggests that Alpha DaRT may offer long-term disease control with minimal side effects for difficult-to-treat cancers.
Alpha Tau Medical, a leader in alpha-radiation cancer therapy, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024. Their CFO, Raphi Levy, will present a corporate overview and update at the event scheduled from 1:30 to 1:55 PM EST in New York. Levy will also be available for one-on-one meetings with investors during the conference. Attendees are encouraged to contact their Jefferies representative to schedule a session.
Alpha Tau Medical reported its Q1 2024 financials and provided a corporate update. The company presented preclinical data showcasing an abscopal immune effect in pancreatic murine tumor models at ESTRO 2024. The first patient in a liver metastases study was treated at McGill University Health Center, with recruitment ongoing for multiple trials. Financially, the company recorded R&D expenses of $6.4 million, marketing expenses of $0.5 million, and G&A expenses of $1.4 million, resulting in a net loss of $8.0 million. Alpha Tau holds $80.7 million in cash, projected to fund operations for at least two years.
Alpha Tau Medical announced the treatment of the first patient with liver cancer metastases using their innovative alpha-radiation cancer therapy, Alpha DaRT. The feasibility and safety study is being conducted at McGill University Health Center in Montreal, Canada. The trial aims to recruit up to 10 patients for a two-staged hepatectomy to resect liver metastases of colorectal cancer. The study will assess the feasibility and safety of delivering Alpha DaRT sources into the liver metastases, as well as its efficacy in terms of radiological and pathological response. CEO Uzi Sofer expressed optimism about the trial's potential to provide new therapeutic options for patients with liver metastases and other challenging cancers.
Alpha Tau Medical presented new preclinical data at the 2024 ESTRO Congress, showcasing the abscopal immune effect of Alpha DaRT in pancreatic murine tumor models. The data revealed a significant reduction in distant tumor growth rate, indicating potential benefits for future clinical trials and patient outcomes. CEO Uzi Sofer highlighted the promising results, emphasizing the therapy's potential in combination with immunotherapy.
Alpha Tau Medical announced that CFO Raphi Levy will present at investor conferences in May 2024. The company, known for its alpha-radiation cancer therapy Alpha DaRT™, will participate in events like Guggenheim Securities Radiopharmaceuticals Day and H.C. Wainwright BioConnect Investor Conference.
FAQ
What is the current stock price of Alpha Tau Medical Ltd. Ordinary Shares (DRTS)?
What is the market cap of Alpha Tau Medical Ltd. Ordinary Shares (DRTS)?
What is Alpha Tau Medical Ltd.?
What is Alpha DaRT?
Where is Alpha Tau conducting clinical trials?
What recent achievements has Alpha Tau announced?
What is the financial condition of Alpha Tau?
What partnerships is Alpha Tau exploring?
How does Alpha DaRT technology work?
What is the ReSTART trial?
What are the future plans for Alpha Tau's manufacturing capabilities?
Where can I find more information about Alpha Tau Medical Ltd.?
